- Home
- ZURA vs EH Comparison
ZURA vs EH Comparison
Compare ZURA & EH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZURA | EH |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Military/Government/Technical |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 455.4M | 435.4M |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ZURA | EH |
|---|---|---|
| Price | $5.57 | $5.93 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 6 | 3 |
| Target Price | $13.00 | ★ $22.47 |
| AVG Volume (30 Days) | ★ 679.8K | 604.8K |
| Earning Date | 05-14-2026 | 05-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $33.23 |
| Revenue Next Year | N/A | $73.83 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.66 | $4.89 |
| 52 Week High | $7.25 | $20.20 |
Technical Indicators
Market Signals| Indicator | ZURA | EH |
|---|---|---|
| Relative Strength Index (RSI) | 54.20 | 55.23 |
| Support Level | $5.62 | $4.89 |
| Resistance Level | $5.87 | $6.98 |
| Average True Range (ATR) | 0.31 | 0.25 |
| MACD | -0.02 | 0.15 |
| Stochastic Oscillator | 53.13 | 82.45 |
Price Performance
Historical ComparisonAbout ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage biotechnology company developing novel medicines for patients with autoimmune and inflammatory diseases, including serious and debilitating conditions with unmet medical need. These diseases are often chronic, biologically complex, and difficult to treat, and many patients do not achieve durable disease control with existing therapies. The company has in-licensed three clinical-stage product candidates: Tibulizumab (ZB-106), a bispecific antibody targeting IL-17A and BAFF; Crebankitug (ZB-168), an IgG1 monoclonal antibody targeting IL-7R; and Torudokimab (ZB-880), an IgG4 monoclonal antibody targeting IL-33.
About EH EHang Holdings Limited ADS
EHang Holdings Ltd is an urban air mobility (UAM) technology platform company focused on autonomous aerial vehicle technology and solutions. The company provides unmanned aerial vehicle (UAV) systems and solutions for air mobility, including passenger transportation and logistics, as well as smart city management and aerial media solutions. Its EH216-S passenger-carrying pilotless eVTOL aircraft has obtained a production certificate and standard airworthiness certificate from the Civil Aviation Administration of China (CAAC).